IRIDEX Past Earnings Performance

Past criteria checks 0/6

IRIDEX has been growing earnings at an average annual rate of 8.5%, while the Medical Equipment industry saw earnings growing at 11.3% annually. Revenues have been growing at an average rate of 7.9% per year.

Key information

8.5%

Earnings growth rate

15.0%

EPS growth rate

Medical Equipment Industry Growth8.9%
Revenue growth rate7.9%
Return on equity-100.5%
Net Margin-18.5%
Last Earnings Update30 Dec 2023

Recent past performance updates

Recent updates

Iridex's Strategic Review Process Should Bear Fruit 'Soon'

Mar 28

Little Excitement Around IRIDEX Corporation's (NASDAQ:IRIX) Revenues

Feb 14
Little Excitement Around IRIDEX Corporation's (NASDAQ:IRIX) Revenues

Will IRIDEX (NASDAQ:IRIX) Spend Its Cash Wisely?

Oct 04
Will IRIDEX (NASDAQ:IRIX) Spend Its Cash Wisely?

Lacklustre Performance Is Driving IRIDEX Corporation's (NASDAQ:IRIX) 32% Price Drop

Aug 12
Lacklustre Performance Is Driving IRIDEX Corporation's (NASDAQ:IRIX) 32% Price Drop

Will IRIDEX (NASDAQ:IRIX) Spend Its Cash Wisely?

Apr 14
Will IRIDEX (NASDAQ:IRIX) Spend Its Cash Wisely?

We're Hopeful That IRIDEX (NASDAQ:IRIX) Will Use Its Cash Wisely

Oct 12
We're Hopeful That IRIDEX (NASDAQ:IRIX) Will Use Its Cash Wisely

Is IRIDEX (NASDAQ:IRIX) Using Too Much Debt?

Feb 25
Is IRIDEX (NASDAQ:IRIX) Using Too Much Debt?

Iridex To Benefit From New Revolutionary Glaucoma Treatment

Jan 11

Analysts Expect Breakeven For IRIDEX Corporation (NASDAQ:IRIX) Before Long

Jan 03
Analysts Expect Breakeven For IRIDEX Corporation (NASDAQ:IRIX) Before Long

IRIDEX says laser therapy now accepted in the European Glaucoma Society guidelines

Dec 23

Revenue & Expenses Breakdown
Beta

How IRIDEX makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGM:IRIX Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Dec 2352-10257
30 Sep 2355-8257
01 Jul 2356-8267
01 Apr 2357-7267
31 Dec 2257-8267
01 Oct 2257-9258
02 Jul 2256-9258
02 Apr 2255-6248
01 Jan 2254-5237
02 Oct 2151-3226
03 Jul 2146-3215
03 Apr 2139-7204
02 Jan 2136-6193
26 Sep 2036-8203
27 Jun 2038-8203
28 Mar 2042-7223
28 Dec 1943-9234
28 Sep 1943-10244
29 Jun 1944-11264
30 Mar 1944-12264
29 Dec 1843-13264
29 Sep 1841-15264
30 Jun 1841-15265
31 Mar 1841-15255
30 Dec 1742-13235
30 Sep 1744-19225
01 Jul 1743-16205
01 Apr 1745-14195
31 Dec 1646-12185
01 Oct 16460175
02 Jul 16461165
02 Apr 16430155
02 Jan 16420145
03 Oct 15419155
04 Jul 15429155
04 Apr 154310155
03 Jan 154310145
27 Sep 14422144
28 Jun 14412144
29 Mar 14402134
28 Dec 13382134
28 Sep 13372124
29 Jun 13351124

Quality Earnings: IRIX is currently unprofitable.

Growing Profit Margin: IRIX is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: IRIX is unprofitable, but has reduced losses over the past 5 years at a rate of 8.5% per year.

Accelerating Growth: Unable to compare IRIX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IRIX is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (2.9%).


Return on Equity

High ROE: IRIX has a negative Return on Equity (-100.5%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.